Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group
Year: 2023
Type: article
Abstract: Acute lymphoblastic leukaemia (ALL) in infancy, defined as ≤1 year of age at diagnosis, is rare with an incidence of 1.8 cases per 100,000 [ 1 ]. KMT2A -gene rearrangements are present in up to 80% of infants with ALL and are associated with a poor prognosis. Historically, collaborative group treatment protocols have focused on intensification of conventional chemotherapy, which can include allogeneic haematopoietic stem cell transplant (HSCT) for high-risk infants, however outcomes for KMT2A -rearranged infant ALL have remained poor due to high relapse rates and treatment-related mortality [ 2 , 3 ]. Given the rarity of the patient population and low survival rates, there is limited data regarding long-term outcomes in survivors of infant ALL in the context of receiving intensive therapy to achieve a cure.
Source: Blood Cancer Journal
Authors: Denitza Mironova, Chitra M. Saraswati, Peter Downie, Chow Yee Lai, Eleanor Cook, Vickyanne Carruthers, Perla Moukhaiber, Fiona Molloy, Joshua Serov, Elizabeth McKinnon, Frank Alvaro, Michael Osborn, Tamas Revesz, Tim Prestidge, Siobhan Cross, Caroline M. Bateman, Andrew S. Moore, Seong Lin Khaw, Marion K. Mateos, Rishi S. Kotecha
Institutions: Princess Margaret Hospital for Children, Perth Children's Hospital, The Kids Research Institute Australia, The University of Western Australia, Royal Children's Hospital, Monash Children’s Hospital, Monash Health, Sydney Children's Hospital, Women's and Children's Hospital, Children's Hospital at Westmead, Westmead Hospital, Children's Health Queensland Hospital and Health Service, John Hunter Hospital, John Hunter Children's Hospital, Starship Children's Health, Christchurch Hospital, UNSW Sydney, Curtin University
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,790
OpenAlex ID: W4387055544